title: sigma recognition sites in brain and peripheral tissues. Characterization and effects of cytochrome P450 inhibitors.
abstract: Binding to sigma sites in subcellular fractions of brain and in crude homogenates from peripheral tissues of the guinea pig was characterized with the [3H]ligands (+)pentazocine and di(2-tolyl)guanidine (DTG). The inhibitory effects of representative sigma compounds and cytochrome P450 inhibitors were evaluated in guinea pig tissues, and the effects of cytochrome P450 induction on sigma binding in the rat were investigated. For both ligands, the majority of sites were localized to the microsomal fractions. The KD values for [3H](+)pentazocine- or [3H]DTG-labeled sigma sites in guinea pig liver and testes were 2-fold lower than those in brain and heart. The number of sites labeled by [3H](+)pentazocine varied, with an order of liver > testes > brain > heart. In contrast, the Bmax values for [3H]DTG-defined sigma sites were greatest in testes, followed by liver, brain and heart. The rank order of potency for representative sigma and P450 compounds was similar in brain, liver and testes for both [3H]ligands, and the potency of selective compounds to displace sigma binding in guinea pig liver failed to correlate with their abilities to inhibit cytochrome P450IID1 activity in human liver. Following induction of cytochrome P450IIB1 with phenobarbital or cytochrome P450IA1 with beta-naphthoflavone, neither the affinity nor the number of sigma sites was altered in rat brain or liver. These results suggest that sigma sites in the periphery are similar to those in the brain, and that the sigma binding site is not identical with cytochrome P450IIB1, P450IA1 or P450IID1.
authors.affiliation: Department of Enzymology and Receptor Biochemistry, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA 19426-0900.
authors.forename: D L
authors.initials: DL
authors.lastname: DeHaven-Hudkins
authors.forename: L F
authors.initials: LF
authors.lastname: Lanyon
authors.forename: F Y
authors.initials: FY
authors.lastname: Ford-Rice
authors.forename: M A
authors.initials: MA
authors.lastname: Ator
mesh_terms: D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D006146:Guanidines / Q000494:pharmacology*; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008099:Liver / Q000187:drug effects; D008297:Male; D010423:Pentazocine / Q000494:pharmacology*; D051381:Rats; D013347:Subcellular Fractions / Q000201:enzymology; D013737:Testis / Q000187:drug effects
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D006146:Guanidines; D007527:Isoenzymes; D003577:Cytochrome P-450 Enzyme System; C050232:1,3-ditolylguanidine; D010423:Pentazocine